Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Ailin LepletierJason MadoreJake S O'DonnellRebecca L JohnstonXian-Yang LiElizabeth McDonaldElizabeth AhernAnna KuchelMelissa EastgateSally-Ann PearsonDomenico MallardoPaolo Antonio AsciertoDaniela MassiBarbara MerelliMario MandalaJames S WilmottAlexander M MenziesCharles LeducBertrand RoutyGeorgina V LongRichard A ScolyerTobias BaldNicola WaddellWilliam C DougallMichele W L TengMark J SmythPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our findings are the first to suggest that tumor CD155 supports an increase in the fraction of PD1+CD8+ T cells in anti-PD1 refractory melanoma tumors and, further, that targeting the CD155 pathway might improve response to anti-PD1 therapy for patients with metastatic melanoma.